Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008⿿2015

Sorenson, 2012, Reflections on the evolution of health technology assessment in Europe, Health Economics, Policy and Law, 7, 25, 10.1017/S1744133111000296 Velasco-Garrido, 2008, Health systems, health policy and health technology assessment Ciani, 2015, Health technology assessment of medical devices: a survey of non-European union agencies, International Journal of Technology Assessment in Health Care, 31, 154, 10.1017/S0266462315000185 Hulstaert, 2012, Pre-market clinical evaluations of innovative high-risk medical devices in Europe, International Journal of Technology Assessment in Health Care, 28, 278, 10.1017/S0266462312000335 Boudard, 2013, Clinical studies of innovative medical devices: what level of evidence for hospital-based health technology assessment?, Journal of Evaluation in Clinical Practice, 19, 697, 10.1111/jep.12024 Cerri, 2014, Decision making by NICE: examining the influences of evidence, process and context, Health Economics, Policy and Law, 9, 119, 10.1017/S1744133113000030 Charokopou, 2015, Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006⿿2013, Value in Health, 18, 284, 10.1016/j.jval.2014.12.008 Dakin, 2006, Yes⿿, ⿿No⿿ or ⿿Yes, but⿿? Multinomial modelling of NICE decision-making, Health Policy, 77, 352, 10.1016/j.healthpol.2005.08.008 Devlin, 2004, Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Economics, 13, 437, 10.1002/hec.864 Linley, 2012, Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors, Pharmacoeconomics, 30, 779, 10.2165/11591530-000000000-00000 Mason, 2010, Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?, Journal of Clinical Oncology, 28, 3234, 10.1200/JCO.2009.26.2758 Cerri, 2014, Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making, European Journal of Health Economics, 15, 681, 10.1007/s10198-013-0514-z George, 2001, Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996), Pharmacoeconomics, 19, 1103, 10.2165/00019053-200119110-00004 Harris, 2008, The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994⿿2004, Medical Decision Making, 28, 713, 10.1177/0272989X08315247 Loge, 2015, Factors influencing reimbursement of medical devices in France, International Journal of Technology Assessment in Health Care, 6, 399, 10.1017/S0266462315000707 Federal Ministry of Health. The Austrian DRG system. Available from: http://www.bmg.gv.at/cms/home/attachments/9/4/3/CH1015/CMS1292515593745/austrian_drg_bmg_2010_end_eng_revised.pdf [accessed 30.09.15]. Mad, 2012, Pre-coverage assessments of new hospital interventions on Austria: methodology and 3 years of experience, International Journal of Technology Assessment in Health Care, 28, 171, 10.1017/S0266462312000025 Balshem, 2011, GRADE guidelines: 3. Rating the quality of evidence, Journal of Clinical Epidemiology, 64, 401, 10.1016/j.jclinepi.2010.07.015 European Network for Health Technology assessment. EUnetHTA. Methodological guideline for REA of pharmaceuticals: Internal validity. Available from: http://www.eunethta.eu/outputs/methodological-guideline-rea-pharmaceuticals-internal-validity [accessed 09.05.16]. Ludwig Boltzmann Institute for Health Technology Assessment. Evaluation of individual medical procedures ⿿ Reports. Available from: http://hta.lbg.ac.at/page/bewertung-medizinischer-einzelleistungen-mel-berichte. European Network for Health Technology assessment. EUnetHTA. Methodological guideline for REA of pharmaceuticals: Criteria for the choice of the most appropriate comparator(s). Available from: http://www.eunethta.eu/outputs/methodological-guideline-rea-pharmaceuticals-criteria-choice-most-appropriate-comparators [accessed 30.09.15]. European Network for Health Technology assessment. EUnetHTA. Methodological guideline for REA of pharmaceuticals: clinical endpoints. Available from: http://www.eunethta.eu/outputs/methodological-guideline-rea-pharmaceuticals-clinical-endpoints [accessed 30.09.15]. European Network for Health Technology assessment. EUnetHTA. Methodological guideline for REA of pharmaceuticals: Surrogate endpoints. Available from: http://www.eunethta.eu/outputs/methodological-guideline-rea-pharmaceuticals-surrogate-endpoints [accessed 30.09.15]. European Commission. Medical devices guidance document ⿿ classification of medical devices, MEDDEV 2.4/1 Rev. 9, June 2010. Available from: http://ec.europa.eu/growth/sectors/medical-devices/guidance/index_en.htm [accessed 30.09.15]. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available from: http://www.R-project.org/ [accessed 30.09.15]. Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Needfor Life Threatening or Irreversibly Debilitating Diseases or Conditions ⿿ Guidance for Industry and Food and Drug Administration Staff. Available from http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393978.pdf [accessed 09.05.16]. Walker, 2012, Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions, Value in Health, 15, 570, 10.1016/j.jval.2011.12.013 Griffin, 2011, Dangerous omissions: the consequences of ignoring decision uncertainty, Health Economics, 20, 212, 10.1002/hec.1586 Brugger, 2014, Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012, International Journal of Technology Assessment in Health Care, 30, 253, 10.1017/S0266462314000233 Tunis, 2006, Coverage options for promising technologies: Medicare's ⿿coverage with evidence development⿿, Health Affairs (Millwood), 25, 1218, 10.1377/hlthaff.25.5.1218 Menon, 2010, Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit, Pharmacoeconomics, 28, 109, 10.2165/11530860-000000000-00000 Martelli, 2016, New French coverage with evidence development for innovative medical devices: improvements and unresolved issues, Value in Health, 17, 10.1016/j.jval.2015.10.006 Vitry, 2014, Managed entry agreements for pharmaceuticals in Australia, Health Policy, 117, 345, 10.1016/j.healthpol.2014.05.005 Godman, 2012, Improving the managed entry of new medicines: sharing experiences across Europe, Expert Review of Pharmacoeconomics & Outcomes Research, 12, 439, 10.1586/erp.12.44 Baeyens, 2015